https://www.thebodypro.com/category/switching-stopping-hiv-treatment-pro
HIV Treatment Strategies

Switching or Stopping HIV Treatment

The Latest

ducks in row
News

This Week in HIV Research: A Break in the Pattern

July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.

By Myles Helfand
medical scale
News

This Week in HIV Research: Tipping the Scales

June 24, 2021: Effect of efavirenz metabolism on weight change; determinants of weight gain when switching meds; metabolic effects of DTG vs. TAF; food security vs. nutrition security.

By Barbara Jungwirth and Myles Helfand
city life
News

This Week in HIV Research: Welcome to the Real World

May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.

By Barbara Jungwirth and Myles Helfand
doctor desk
Features

Long-Acting ART Rollout: 3 Considerations for Clinicians

Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.

By Larry Buhl
medical scale
Conference Coverage

More Research Points to Weight Increases on TAF-Containing HIV Treatment

Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.

By Michael Broder
slacklining
News

This Week in HIV Research: So Many Relative Risks

July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.

By Barbara Jungwirth and Myles Helfand
Newton's Cradle
News

When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds

Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.

By Martha Kempner
selective focus image of Gilead Truvada for PrEP
News

This Week in HIV Research: PrEP So White

May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

By Barbara Jungwirth and Myles Helfand
droplet of blood
News

This Week in HIV Research: How Dangerous Is Low-Level Viremia?

May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.

By Barbara Jungwirth and Myles Helfand
pill bottles and cash
Conference Coverage

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

By Myles Helfand